In the four-week study, the lead compounds targeted GPR75 to influence central energy homeostasis. Unlike treatments that prioritize simple mass reduction, these molecules demonstrated a preferential loss of adipose tissue, shrinking fat stores by 33–50% while preserving lean muscle mass. The results also extended to broader metabolic health, showing significant drops in fasting blood glucose, HbA1c levels, and systemic inflammatory markers like CRP and IL-18.

Beyond weight metrics, the data revealed improved liver function and lipid profiles, including lower LDL cholesterol and optimized ALT/AST levels. CEO Luba Greenwood stated that the findings support GPR75 as a key player in systemic metabolic regulation, moving the focus toward high-quality weight loss. The company’s research aligns with large-scale human genetic studies of 640,000 individuals, which previously linked GPR75 loss-of-function variants to lower BMI and a reduced risk of obesity. Mwyngil is now moving forward with translational activities to select a final development candidate from its current pipeline of brain-penetrant, orally active molecules.